Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M104,967Revenue (TTM) $M23,777Net Margin (%)23.0Altman Z-Score2.4
Enterprise Value $M128,280EPS (TTM) $3.3Operating Margin %34.2Piotroski F-Score7
P/E(ttm)19.5Beneish M-Score-2.1Pre-tax Margin (%)29.6Higher ROA y-yY
Price/Book22.610-y EBITDA Growth Rate %--Quick Ratio1.4Cash flow > EarningsY
Price/Sales4.55-y EBITDA Growth Rate %0.8Current Ratio1.6Lower Leverage y-yN
Price/Free Cash Flow14.1y-y EBITDA Growth Rate %132ROA % (ttm)11.3Higher Current Ratio y-yY
Dividend Yield %3.4PEG24.0ROE % (ttm)135Less Shares Outstanding y-yN
Payout Ratio %63.0Shares Outstanding M1,617ROIC % (ttm)26.4Gross Margin Increase y-yY

Gurus Latest Trades with ABBV

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
ABBVJoel Greenblatt 2016-03-31 Add0.28%$51.18 - $59.24
($55.77)
$ 64.9016%Add 216.32%645,835
ABBVJohn Paulson 2016-03-31 Sold Out -0.05%$51.18 - $59.24
($55.77)
$ 64.9016%Sold Out0
ABBVDavid Dreman 2016-03-31 Add0.03%$51.18 - $59.24
($55.77)
$ 64.9016%Add 16.28%30,542
ABBVNWQ Managers 2016-03-31 Add0.02%$51.18 - $59.24
($55.77)
$ 64.9016%Add 3.64%781,850
ABBVKen Fisher 2016-03-31 Reduce-0.02%$51.18 - $59.24
($55.77)
$ 64.9016%Reduce -20.51%743,284
ABBVDodge & Cox 2016-03-31 Reduce$51.18 - $59.24
($55.77)
$ 64.9016%Reduce -0.07%33,232
ABBVMario Gabelli 2016-03-31 Reduce$51.18 - $59.24
($55.77)
$ 64.9016%Reduce -12.66%35,460
ABBVNWQ Managers 2015-12-31 Reduce-0.65%$48.27 - $64.13
($57.69)
$ 64.9012%Reduce -50.59%754,413
ABBVFirst Eagle Investment 2015-12-31 Sold Out -0.14%$48.27 - $64.13
($57.69)
$ 64.9012%Sold Out0
ABBVJoel Greenblatt 2015-12-31 Add0.08%$48.27 - $64.13
($57.69)
$ 64.9012%Add 179.54%204,171
ABBVJohn Paulson 2015-12-31 Buy 0.05%$48.27 - $64.13
($57.69)
$ 64.9012%New holding139,700
ABBVDavid Dreman 2015-12-31 Reduce-0.03%$48.27 - $64.13
($57.69)
$ 64.9012%Reduce -15.80%26,267
ABBVMario Gabelli 2015-12-31 Reduce$48.27 - $64.13
($57.69)
$ 64.9012%Reduce -7.58%40,600
ABBVKen Fisher 2015-12-31 Add$48.27 - $64.13
($57.64)
$ 64.9013%Add 0.77%935,104
ABBVFirst Eagle Investment 2015-09-30 Add0.05%$52.5 - $71.23
($65.09)
$ 64.90-0%Add 55.71%1,056,150
ABBVDavid Dreman 2015-09-30 Add0.02%$52.5 - $71.23
($65.09)
$ 64.90-0%Add 10.27%31,197
ABBVJoel Greenblatt 2015-09-30 Add0.02%$52.5 - $71.23
($65.09)
$ 64.90-0%Add 117.34%73,037
ABBVKen Fisher 2015-09-30 Reduce-0.01%$52.5 - $71.23
($65.09)
$ 64.90-0%Reduce -7.82%927,959
ABBVMario Gabelli 2015-09-30 Reduce$52.5 - $71.23
($65.09)
$ 64.90-0%Reduce -5.65%43,930
ABBVDodge & Cox 2015-09-30 Reduce$52.5 - $71.23
($65.09)
$ 64.90-0%Reduce -2.92%33,255
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

ABBV is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


ABBV: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Schumacher Laura JExecutive Vice President 2016-06-24Sell186,106$60.038.11view
GONZALEZ RICHARD AChairman of the Board and CEO 2016-06-02Sell285,953$63.821.69view
GONZALEZ RICHARD AChairman of the Board and CEO 2016-05-11Sell39,000$63.81.72view
HURWICH THOMAS A.VP, Controller 2016-05-10Sell6,000$63.592.06view
RICHMOND TIMOTHY J.SVP, Human Resources 2016-05-10Sell21,583$63.522.17view
ALBAN CARLOSEVP, Commercial Operations 2016-05-10Sell47,438$63.522.17view
Schumacher Laura JExecutive Vice President 2016-03-08Sell25,000$56.0915.71view
RICHMOND TIMOTHY J.SVP, Human Resources 2016-03-01Sell12,866$55.0517.89view
SALEKI-GERHARDT AZITASVP, Operations 2016-02-29Sell1,776$55.3817.19view
HURWICH THOMAS A.VP, Controller 2016-02-29Sell1,444$55.2517.47view

Press Releases about ABBV :

Quarterly/Annual Reports about ABBV:

News about ABBV:

Articles On GuruFocus.com
9 Best Stocks for Value Investors This Week Jul 26 2016 
An Unfair Valuation Makes a Great Investment Jul 15 2016 
These Are the Only Dividend Aristocrats I Would Consider Today Jul 07 2016 
5 Attractive Biotechnology Stocks for Healthy Long-term Returns Jun 10 2016 
Weekly CEO Sells Highlight Jun 06 2016 
Wall Street Estimates and Biopharma Value Investing Jun 02 2016 
Dividend and Value Opportunities in the Large-Cap Pharmaceutical Space Apr 05 2016 
A Cheap Dividend Aristocrat Yielding Over 4% Mar 02 2016 
John Paulson Bulks Up Health Care Bet Feb 17 2016 
Gilead, Johnson & Johnson or Roche? Feb 11 2016 

More From Other Websites
Biotech Stock Roundup: Biogen Q2 Results Impress, Gilead HCV Franchise Under Pressure Jul 27 2016
What to Look for When AbbVie (ABBV) Reports Q2 Results Jul 27 2016
Top 10 Dividend Aristocrats to Buy at a Discount Now Jul 27 2016
Short Sellers Get Selective on Major Pharma Jul 27 2016
TauRx Alzheimer's drug fails in large study; some benefit seen Jul 27 2016
Experimental Tau Protein Drug Tangled Up in Late-Stage Alzheimer's Study Failure Jul 27 2016
[$$] Gormley's Take: Offsetting IPO Market Slowdown, Health-Care M&A Surges in First Half Jul 27 2016
AbbVie (ABBV) Q2 Earnings: Will the Stock Pull a Surprise? Jul 26 2016
Six Major Biotech Acquisitions You Could See In 2016 (Part 3) Jul 26 2016
Top Analyst Thinks Big Pharmaceutical Stocks Will Outperform the Rest of 2016 Jul 26 2016
Enanta Announces the U.S. Food and Drug Administration has approved AbbVie’s New, Once-Daily... Jul 25 2016
AbbVie Receives U.S. FDA Approval of Once-Daily VIEKIRA XR™ (dasabuvir, ombitasvir, paritaprevir... Jul 25 2016
AbbVie And Bristol-Myers Squibb Strike Oncology Clinical Alliance To Assess Rova-T plus Opdivo And... Jul 25 2016
Gilead Sciences: What Do Analysts Recommend? Jul 25 2016
Gilead Sciences Kicks Off 5 Big Pharma Earnings This Week Jul 25 2016
AbbVie and Bristol-Myers Squibb Announce Oncology Clinical Collaboration to Evaluate the Combination... Jul 25 2016
AbbVie and Bristol-Myers Squibb to collaborate on lung cancer clinical trial Jul 25 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)